Clinical trials: Lupus Nephritis (LN)
Lupus Nephritis
Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)
Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus nephritis (LN).
- Trial name
- NCT05540665
- Testing
- Daxdilimab
- Where
- 52 sites in United States, Argentina and 10 more
- Volunteers
- 19 people
- Sponsor
- Amgen
Lupus Nephritis, Immunoglobulin A Nephropathy
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition…
- Trial name
- SANCTUARY (NCT04564339)
- Testing
- Ravulizumab, Background Therapy
- Where
- 64 sites in United States, Australia and 10 more
- Volunteers
- 123 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Lupus Nephritis
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
This was a pivotal, randomized, double-blind, placebo-controlled trial evaluating at Week 52 the efficacy and safety of secukinumab versus placebo in patients with active lupus nephritis (ISN/RPS Class III or IV, with or without…
- Trial name
- SELUNE (NCT04181762)
- Testing
- secukinumab
- Where
- 105 sites in United States, Argentina and 32 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis, Immunoglobulin A Nephropathy
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤…
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
- Trial name
- NCT05097989
- Testing
- ALXN2050
- Where
- 71 sites in United States, Argentina and 14 more
- Volunteers
- 100 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
IgAN, LN
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
The purpose of this study was to evaluate the safety and tolerability of OMS721 (narsoplimab) in participants with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), Membranous Nephropathy (MN), and Complement Component 3…
- Conditions
- IgAN, LN, MN, C3G
- Trial name
- NCT02682407
- Testing
- OMS721 (narsoplimab)
- Where
- 12 sites in United States, Hong Kong
- Volunteers
- 31 people
- Sponsor
- Omeros Corporation
Lupus Nephritis
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
The purpose of this study is to characterize the safety and tolerability of ixazomib when administered as multiple oral doses at escalating dose levels in participants with lupus nephritis.
- Trial name
- NCT02176486
- Testing
- Ixazomib
- Where
- 35 sites in United States, France and 5 more
- Volunteers
- 12 people
- Sponsor
- Takeda
Lupus Nephritis
A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)
This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.
- Trial name
- NCT02550652
- Testing
- Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Methylprednisolone
- Where
- 46 sites in United States, Argentina and 10 more
- Volunteers
- 126 people
- Sponsor
- Hoffmann-La Roche
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
This was a Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF…
- Trial name
- LUNAR (NCT00282347)
- Testing
- Rituximab, Mycophenolate mofetil, Methylprednisolone
- Volunteers
- 144 people
- Sponsor
- Genentech, Inc.